0001193125-26-132014
SEC filingSensei Biotherapeutics continued to operate at a loss in FY2025, though financial performance showed improvement in operating and net loss metrics compared to the prior year, reflecting ongoing cost management amid a strategic transition following the Faeth acquisition.
Sensei Biotherapeutics reported continued operating and net losses in FY2025, consistent with its stage as a clinical-stage biopharmaceutical company with no product revenue. However, both operating income and net income showed year-over-year improvement, with operating loss decreasing to -$22.3 million from -$32.6 million and net loss narrowing to -$21.1 million from -$30.2 million. This reduction reflects successful cost containment measures ahead of the Faeth Therapeutics acquisition, although financial results pertain only to pre-acquisition operations.
Net cash used in operating activities improved to -$20.5 million in FY2025, down from -$24.7 million in FY2024, aligning with tighter control over operating expenditures. Free cash flow, calculated as net cash from operations less capital expenditures, was -$20.5 million, with capital spending falling materially to $16,000 from $146,000. This decline underscores limited infrastructure investment during the reporting period, as resources were conserved during the transition phase.
As highlighted in Item 7, later-stage clinical programs typically drive higher R&D costs, but Sensei has not yet advanced candidates to such stages. The company expenses all research and development costs as incurred, contributing to sustained losses. Despite current cost discipline, management explicitly anticipates higher general and administrative expenses post-Faeth integration to support expanded operations and pipeline development.